United States Patent 8,609,701: Pirfenidone Liver-Abnormality Retreatment Claims and Patent Landscape
U.S. Patent No. 8,609,701 protects a narrow method of re-administering pirfenidone after a patient develops a Grade 2 ALT or AST abnormality following an initial pirfenidone course. The central protected concept is not pirfenidone itself, idiopathic pulmonary fibrosis treatment generally, or routine dose titration. It is the decision to restart or continue pirfenidone, after liver-function abnormalities, at specified daily doses, with optional interruption, laboratory normalization, stepwise re-titration, food administration, and monitoring.
The patent is strategically important because a generic manufacturer may be able to sell pirfenidone for unpatented uses while facing infringement risk if its labeling instructs physicians to retreat patients after ALT or AST elevations using the claimed dosing sequence.
What patent protects pirfenidone liver-abnormality retreatment?
| Field |
Patent information |
| U.S. patent |
8,609,701 |
| Title |
Methods for treating patients with pirfenidone |
| Patent type |
Method-of-treatment patent |
| Active ingredient |
Pirfenidone |
| Principal disease |
Idiopathic pulmonary fibrosis |
| Core biomarker |
ALT or AST |
| Trigger event |
Grade 2 liver-function abnormality after first pirfenidone administration |
| Main retreatment dose |
At least 1,600 mg/day or 1,602 mg/day |
| Higher dose |
2,400 mg/day or 2,403 mg/day |
| Other doses |
Approximately 800/801 mg/day and 1,600/1,602 mg/day |
| Administration |
Three times daily with food in dependent claims |
| Patent holder lineage |
InterMune, subsequently acquired by Roche/Genentech |
| Grant date |
December 17, 2013 |
| Expected statutory term |
February 2027, subject to the applicable patent-term records and any term adjustment |
The patent does not claim a pirfenidone molecule, tablet composition, capsule, salt, polymorph, or manufacturing process. Its claims are directed to clinical management of a patient already receiving pirfenidone.
How broad is claim 1 of U.S. Patent 8,609,701?
Claim 1 contains the patent's essential limitations:
- The patient must need pirfenidone.
- The patient must have a Grade 2 abnormality in ALT or AST.
- The abnormality must occur after a first pirfenidone administration.
- The method must include a second pirfenidone administration.
- The second administration must include at least 1,600 mg/day or 1,602 mg/day.
The claim is therefore narrower than a general claim covering treatment of idiopathic pulmonary fibrosis with pirfenidone. It requires a specific adverse-event history and a particular retreatment decision.
What does “Grade 2” mean?
The claim uses a toxicity-grade concept associated with clinical adverse-event grading. Under the Common Terminology Criteria for Adverse Events, Grade 2 ALT or AST elevation generally corresponds to greater than 3.0 to 5.0 times the upper limit of normal, depending on the applicable laboratory and grading version.[1]
The patent's claim does not appear to cover every mild liver-enzyme elevation. A Grade 1 elevation, a nonspecific liver abnormality, or an abnormality unrelated to ALT or AST would not satisfy the express biomarker limitation.
What does “after a first administration” require?
The first administration establishes the initial pirfenidone exposure. The second administration is the later course that follows the liver-function abnormality. The claim does not require that the first course reach 2,400 mg/day. Depending on the construction of the claim, the first course could involve a lower or higher pirfenidone dose, provided the claimed Grade 2 abnormality occurs after that exposure.
Why are 1,600 mg/day and 1,602 mg/day both recited?
Pirfenidone dosing can be expressed as a nominal daily dose or as the aggregate of three daily administrations. The 1,602 mg/day figure corresponds to approximately 534 mg three times daily, while 2,403 mg/day corresponds to approximately 801 mg three times daily. These alternative numbers may be intended to capture both labeled tablet-strength dosing and calculated daily totals.
What do claims 2 through 19 add?
The dependent claims create multiple infringement pathways.
| Claim group |
Added limitation |
Commercial significance |
| 2 |
Retreat at 2,400 or 2,403 mg/day |
Covers full-dose retreatment |
| 3 |
Lower dose before reaching 2,400/2,403 mg/day |
Captures staged re-escalation |
| 4 |
Stop pirfenidone for about one week or until normalization |
Covers a treatment interruption |
| 5 |
Use 1,600/1,602 mg/day for about one week before higher dosing |
Covers intermediate-dose reintroduction |
| 6, 15 |
Use 800/801 mg/day, then 1,600/1,602 mg/day |
Covers two-step titration |
| 7 |
Stop treatment before the 2,400/2,403 mg/day retreatment |
Alternative interruption route |
| 8, 13 |
Administer three times daily with food |
Aligns with commercial dosing instructions |
| 9, 14 |
Measure ALT or AST |
Adds monitoring as a claimed step |
| 10, 11 |
Restart below 1,600 mg/day, with possible interruption |
Covers lower-dose retreatment |
| 12 |
Restart at 800/801 mg/day |
Captures the initial step in re-titration |
| 16 |
Administer approximately 1,800 mg/day |
Covers an intermediate target dose |
| 17-18 |
Fibrosis, renal fibrosis, vascular fibrosis, or scleroderma |
Extends beyond the principal pulmonary indication |
| 19 |
Idiopathic pulmonary fibrosis |
Narrows the claim to the approved commercial disease |
Because the claims use “comprising,” performance of the listed steps generally does not avoid the claim merely because additional clinical steps are performed. A regimen that includes a claimed 800 mg/day step, a laboratory check, a treatment interruption, and later administration of 2,400 mg/day may satisfy more than one dependent claim.
What formulations are protected by U.S. Patent 8,609,701?
The patent does not materially protect a particular formulation.
Its claims identify pirfenidone by active ingredient and daily dose. Claim 8 adds administration three times daily with food, but it does not require a particular excipient system, coating, tablet hardness, dissolution profile, capsule shell, or manufacturing method.
A generic pirfenidone tablet could fall within the claims if it is used under the claimed retreatment protocol. The same generic product could avoid formulation-patent claims held elsewhere, while still presenting method-of-use risk under this patent.
The distinction is important:
- Product claims typically attach to the drug product itself.
- Method claims attach to the conduct of treatment.
- U.S. Patent 8,609,701 primarily creates the second type of risk.
What FDA regulatory status and Orange Book issues apply?
Pirfenidone is FDA-approved under the Esbriet brand for adults with idiopathic pulmonary fibrosis. Roche acquired InterMune, the original commercial sponsor, in 2014.[2][3]
The FDA-approved Esbriet regimen includes titration to 2,403 mg/day, administered in three divided doses with food. The prescribing information also addresses liver-function testing, dose modification, interruption, and re-escalation after hepatic laboratory abnormalities.[3]
| Regulatory issue |
Assessment |
| FDA product |
Esbriet |
| Active ingredient |
Pirfenidone |
| Approved indication |
Idiopathic pulmonary fibrosis |
| Standard full dose |
2,403 mg/day |
| Administration |
Three times daily with food |
| Liver monitoring |
ALT, AST, bilirubin and related testing under labeling |
| Relevant patent issue |
Whether the approved labeling practices the patented retreatment method |
| Regulatory pathway for generics |
ANDA, typically with patent certifications |
| Patent listing significance |
An Orange Book-listed method patent can require a Paragraph IV or other appropriate certification |
The Orange Book analysis must distinguish three dates:
- Patent expiration.
- Any pediatric exclusivity or regulatory exclusivity.
- The date on which a generic applicant may obtain approval and the date on which it may launch.
For U.S. Patent 8,609,701, the ordinary patent-term endpoint is generally identified as February 2027 based on the patent family priority and term records. Patent expiration does not itself establish that a generic launched on that date. Launch may be delayed by litigation, settlement terms, other listed patents, regulatory review, or commercial strategy.[4]
When does pirfenidone lose exclusivity?
Pirfenidone's principal molecule and early-use patent protection are separate from the retreatment patent.
The relevant exclusivity layers are:
| Exclusivity layer |
Relevance |
| Original composition and early-use patents |
Historically protected pirfenidone and broad therapeutic use |
| FDA regulatory exclusivity |
Governed approval and orphan-drug provisions |
| U.S. Patent 8,609,701 |
Covers hepatic-abnormality retreatment methods |
| Later method or formulation patents |
May create separate launch constraints |
| Pediatric exclusivity |
Can extend listed patent protection where granted |
Pirfenidone is a small molecule, so biosimilar exclusivity does not apply. Generic manufacturers use the ANDA pathway, not the 351(k) biosimilar pathway.
The commercial exclusivity question is therefore a generic patent question, not a biologic interchangeability question.
Which companies are most likely to challenge the patent?
Generic pirfenidone manufacturers with ANDAs have the strongest incentive to challenge method claims that could delay a full-label launch. Potential challengers include manufacturers seeking approval for pirfenidone tablets or capsules under an ANDA, including large generic companies and regional suppliers.
A Paragraph IV challenge could target:
- Anticipation by prior pirfenidone treatment guidance.
- Obviousness based on known dose interruption and re-titration practices.
- Lack of written description for the full combination of Grade 2 ALT/AST abnormality and the specified retreatment doses.
- Lack of enablement across the claimed disease and toxicity populations.
- Claim construction of “Grade 2,” “first administration,” “second administration,” “about one week,” and “until biomarkers ... are within normal limits.”
- Noninfringement based on a proposed label that omits or narrows the retreatment instructions.
The patent's vulnerability is likely highest on obviousness and claim-construction grounds. Dose interruption, laboratory monitoring, and re-escalation are clinically conventional concepts. The patent owner's strongest response would be that the specific combination of a defined Grade 2 ALT/AST event, treatment interruption, stepwise dosing, and return to a therapeutic dose was not taught or suggested in a single prior-art regimen.
What patent litigation affects pirfenidone?
The relevant litigation question is not limited to whether U.S. Patent 8,609,701 was challenged. A generic applicant can face a layered patent estate in which:
- One patent covers the active ingredient or broad use.
- Another covers the approved indication.
- Another covers dose titration or adverse-event management.
- Later patents cover formulations, packaging, or delivery.
For a method-of-use patent, litigation risk depends heavily on the proposed ANDA labeling. A generic may argue that its label does not instruct physicians to perform the patented retreatment method. The innovator may respond under induced-infringement principles if the label recommends the patented sequence or if the protocol is the standard labeled use.
The key litigation dates for diligence are:
| Event |
Importance |
| ANDA filing |
Establishes the generic challenge |
| Paragraph IV notice |
Starts the patent-holder response period |
| District-court filing |
Can trigger a 30-month approval stay |
| Claim-construction ruling |
Defines scope of the retreatment claims |
| Summary judgment |
May resolve infringement or validity |
| Trial or settlement |
Determines launch timing |
| FDA approval date |
Does not necessarily equal commercial launch |
| Patent expiration |
Removes infringement liability for post-expiration conduct |
No conclusion about a specific generic company's litigation position should be drawn solely from the existence of this patent. Patent-by-patent ANDA certifications and settlement terms control.
How strong is the patent estate for pirfenidone?
Strengths
- The claims are tied to a clinically recognizable scenario: liver-enzyme elevation after initial exposure.
- The full-dose retreatment regimen aligns with the approved Esbriet dosing structure.
- Dependent claims cover several practical titration paths rather than a single dose.
- Claims 8, 9, 13 and 14 track routine label instructions, which can increase induced-infringement exposure for a full-label generic.
- Claims 17 through 19 provide disease-specific fallback positions.
Weaknesses
- The claims are method claims, not product claims.
- The central elements involve routine clinical actions: stopping therapy, measuring liver enzymes, waiting for normalization, and restarting at a lower dose.
- “Grade 2” may create a technical proof issue if the patent does not define the grading system with sufficient precision.
- “About one week” and “until biomarkers ... are within normal limits” create factual and construction questions.
- A generic may pursue a label that omits the patented retreatment instructions, subject to FDA requirements and induced-infringement analysis.
- The patent term ends substantially earlier than a newly issued formulation patent would if later patents exist.
What generic launch scenarios exist for pirfenidone?
Full-label launch after patent expiry
A generic can seek approval with labeling that tracks the full Esbriet prescribing information and launch after all relevant blocking patents expire or are otherwise resolved.
Paragraph IV launch after a successful challenge
A challenger may launch before expiry if it obtains a favorable judgment, reaches a license, or accepts litigation risk. The commercial value of this route depends on whether the patent is the last meaningful barrier.
Carve-out or section viii strategy
A generic may attempt to omit patented method-of-use information from its labeling. This approach is difficult if the claimed retreatment protocol is embedded in the FDA-approved labeling and is necessary for safe use, but it can materially reduce induced-infringement exposure if legally and regulatorily available.
Settlement launch
A settlement may establish a licensed entry date before patent expiration. The economic terms can include royalties, supply arrangements, authorized-generic provisions, or restrictions on launch conditions. A settlement date should not be treated as evidence that the patent is valid or infringed.
What is the geographic coverage of U.S. Patent 8,609,701?
The patent has territorial effect in the United States only. It does not directly prevent use, sale, or importation in Canada, Europe, Japan, China, or other jurisdictions.
The corresponding international landscape must be analyzed separately because:
- Patent families may have different claim scope.
- National-phase applications may have been abandoned.
- Patent terms may differ.
- Regulatory labels may use different liver-monitoring protocols.
- Generic litigation standards vary by jurisdiction.
A U.S. patent can block U.S. conduct involving a patented treatment method, including certain acts relating to an imported product, but it is not a global exclusivity right.
What manufacturing and intellectual-property barriers remain?
U.S. Patent 8,609,701 is not a manufacturing barrier. It does not claim:
- Pirfenidone synthesis.
- A crystalline form.
- A tablet coating.
- A controlled-release system.
- A pharmaceutical composition.
- A manufacturing process.
- A specific excipient combination.
The principal barrier is label-based method-of-use exposure. Manufacturing freedom to operate and clinical-use freedom to operate must be assessed independently.
Key Takeaways
- U.S. Patent 8,609,701 is a narrow pirfenidone method-of-treatment patent.
- Its core limitation is retreatment after a Grade 2 ALT or AST abnormality following initial pirfenidone exposure.
- The principal dose thresholds are 1,600/1,602 mg/day and 2,400/2,403 mg/day.
- Dependent claims cover interruption, laboratory normalization, staged re-titration, food administration, three-times-daily dosing, and ALT/AST monitoring.
- The patent does not protect pirfenidone as a molecule or a formulation.
- Pirfenidone is a small molecule; biosimilar exclusivity is not relevant.
- The ordinary patent-term endpoint is generally February 2027.
- Generic risk depends heavily on ANDA labeling and whether the label instructs the claimed retreatment method.
- The main validity pressure points are obviousness, the definition of Grade 2, and the precision of the retreatment sequence.
- The patent should be evaluated as one layer of the Esbriet estate rather than as the sole barrier to generic entry.
References
-
U.S. Department of Health and Human Services, National Cancer Institute. (2017). Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. National Institutes of Health.
-
U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,609,701: Methods for treating patients with pirfenidone. Washington, DC.
-
U.S. Food and Drug Administration. (2023). Esbriet (pirfenidone) prescribing information. Genentech USA, Inc.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
